BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34714913)

  • 21. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression.
    Senawong T; Peterson VJ; Leid M
    Arch Biochem Biophys; 2005 Feb; 434(2):316-25. PubMed ID: 15639232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.
    Finotti A; Gasparello J; Breveglieri G; Cosenza LC; Montagner G; Bresciani A; Altamura S; Bianchi N; Martini E; Gallerani E; Borgatti M; Gambari R
    Exp Hematol; 2015 Dec; 43(12):1062-1071.e3. PubMed ID: 26342260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
    Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
    J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of Trib1 in myeloid leukaemogenesis and differentiation.
    Nakamura T
    Biochem Soc Trans; 2015 Oct; 43(5):1104-7. PubMed ID: 26517931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Curtiss BM; VanCampen J; Macaraeg J; Kong GL; Taherinasab A; Tsuchiya M; Yashar WM; Tsang YH; Horton W; Coleman DJ; Estabrook J; Lusardi TA; Mills GB; Druker BJ; Maxson JE; Braun TP
    Leukemia; 2022 Jul; 36(7):1781-1793. PubMed ID: 35590033
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
    Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RUNX1 regulates corepressor interactions of PU.1.
    Hu Z; Gu X; Baraoidan K; Ibanez V; Sharma A; Kadkol S; Munker R; Ackerman S; Nucifora G; Saunthararajah Y
    Blood; 2011 Jun; 117(24):6498-508. PubMed ID: 21518930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.
    Mattes K; Geugien M; Korthuis PM; Brouwers-Vos AZ; Fehrmann RSN; Todorova TI; Steidl U; Vellenga E; Schepers H
    Exp Hematol; 2019 May; 73():38-49.e7. PubMed ID: 30986495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.
    Will B; Vogler TO; Narayanagari S; Bartholdy B; Todorova TI; da Silva Ferreira M; Chen J; Yu Y; Mayer J; Barreyro L; Carvajal L; Neriah DB; Roth M; van Oers J; Schaetzlein S; McMahon C; Edelmann W; Verma A; Steidl U
    Nat Med; 2015 Oct; 21(10):1172-81. PubMed ID: 26343801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCL11A expression in acute phase chronic myeloid leukemia.
    Yin J; Zhang F; Tao H; Ma X; Su G; Xie X; Xu Z; Zheng Y; Liu H; He C; Mao ZJ; Wang Z; Chang W; Gale RP; Wu D; Yin B
    Leuk Res; 2016 Aug; 47():88-92. PubMed ID: 27285855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.
    Burda P; Curik N; Kokavec J; Basova P; Mikulenkova D; Skoultchi AI; Zavadil J; Stopka T
    Mol Cancer Res; 2009 Oct; 7(10):1693-703. PubMed ID: 19825991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.
    Burda P; Vargova J; Curik N; Salek C; Papadopoulos GL; Strouboulis J; Stopka T
    PLoS One; 2016; 11(3):e0152234. PubMed ID: 27010793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases.
    Yin J; Xie X; Ye Y; Wang L; Che F
    Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31654056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.